SCHEMBL24477293

SCHEMBL24477293

Cc1cc(C)n2nc(C)c(C(=O)NCc3ccc(-c4ccco4)cc3)c2n1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
APOBEC3A P31941 1/20 0.50
ALDH1A1 P00352 7/20 0.47
KDM4E B2RXH2 5/20 0.47
KMT2A Q03164 3/20 0.47
HPGD P15428 4/20 0.47
CYP1A1 P04798 1/20 0.46
ADORA2A P29274 8/20 0.45
ADORA3 P0DMS8 7/20 0.45
HSD17B10 Q99714 2/20 0.45
ADORA1 P30542 7/20 0.45
ADORA2B P29275 1/20 0.44
MEN1 O00255 2/20 0.42
MAPT P10636 2/20 0.42
PKM P14618 1/20 0.42
BLM P54132 1/20 0.42
TDP1 Q9NUW8 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24477299 0.83 ALDH1A1 (0.71) ALDH1A1KDM4EKMT2AHPGDCYP1A1
SCHEMBL22472811 0.80 APOBEC3A (0.47) APOBEC3AALDH1A1KDM4EKMT2AHPGD
SCHEMBL22472753 0.79 APOBEC3A (0.46) APOBEC3AALDH1A1KDM4EKMT2AHPGD
SCHEMBL15246125 0.74 ALDH1A1 (0.54) ALDH1A1KDM4EKMT2AHPGDMEN1
SCHEMBL24477294 0.74 APOBEC3A (0.39) APOBEC3AALDH1A1KDM4EKMT2AHPGD
SCHEMBL16644239 0.74 POLB (0.56) ALDH1A1KMT2AMEN1MAPTSMN1; SMN2
SCHEMBL24477300 0.74 ALDH1A1 (0.72) ALDH1A1KDM4EKMT2AHPGDCYP1A1
SCHEMBL15246118 0.74 ALDH1A1 (0.54) ALDH1A1KDM4EKMT2AHPGDMEN1
SCHEMBL22767522 0.73 ALDH1A1 (0.41) APOBEC3AALDH1A1KDM4EKMT2AHPGD
SCHEMBL24477289 0.72 ALDH1A1 (0.43) ALDH1A1KDM4EKMT2AHPGDCYP1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220169652-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS LYSOSOMAL THERAPEUTICS INC. 2022-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220169652-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS PARK7, PNP, GAA APOBEC3A 320/4885ALDH1A1 1213/4885KDM4E 899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.